Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 7/20 | 0.35 |
| ▸ | MME | P08473 | 3/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 7/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335122 | 0.84 | ALDH1A1 (0.37) | SMN1; SMN2PPARGMMECYP4F2CYP4A11 | |
| SCHEMBL6724780 | 0.82 | PPARA (0.42) | SMN1; SMN2PPARGCYP4F2CYP4A11PPARA | |
| SCHEMBL6724782 | 0.77 | CYP4F2 (0.49) | SMN1; SMN2PPARGCYP4F2CYP4A11PPARA | |
| SCHEMBL6731797 | 0.77 | CYP4F2 (0.51) | PPARGCYP4F2CYP4A11PPARAPPARD | |
| SCHEMBL5379702 | 0.76 | ESR1 (0.45) | SMN1; SMN2PPARGPPARACYP2D6CYP2C19 | |
| SCHEMBL5379694 | 0.76 | ESR1 (0.45) | SMN1; SMN2PPARGPPARACYP2D6CYP2C19 | |
| SCHEMBL6723554 | 0.75 | CYP4F2 (0.40) | SMN1; SMN2PPARGCYP4F2CYP4A11PPARA | |
| Hydrochloric Acid SCHEMBL6724404 | 0.74 | PPARA (0.39) | PPARGPPARAPPARD | |
| SCHEMBL6720362 | 0.73 | MAPK1 (0.40) | SMN1; SMN2PPARGCYP4F2CYP4A11PPARA | |
| SCHEMBL6727094 | 0.73 | GAA (0.46) | SMN1; SMN2PPARGPPARACYP3A4PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | SMN1; SMN2 3054/4885PPARG 379/4885MME 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.